A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis

Trial Profile

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Apremilast (Primary)
  • Indications Psoriatic arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms PALACE-1
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 17 Jun 2017 Results assessing the long-term safety of Apremilast treatment (for up to 4 years) using pooled data (n=1493) from the phase 3 PALACE-1, 2, and 3 studies, presented at the 18th Annual Congress of the European League Against Rheumatism.
    • 17 Jun 2017 Results of post-hoc analysis assessing Apremilast treatment outcomes, using pooled data from three phase III randomized controlled trials (PALACE 1-3) presented at the 18th Annual Congress of the European League Against Rheumatism.
    • 17 Jun 2017 Results of pooled analysis from Esteem and Palace 1-3 Phase 3 Trials presented at the 18th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top